Impact of RAS, BRAF mutations and microsatellite status in peritoneal metastases from colorectal cancer treated with cytoreduction + HIPEC: scoping review

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play c...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of hyperthermia Ročník 42; číslo 1; s. 2479527
Hlavní autoři:	Zucchini, Valentina, D’Acapito, Fabrizio, Rapposelli, Ilario Giovanni, Framarini, Massimo, Di Pietrantonio, Daniela, Turrini, Riccardo, Pozzi, Eleonora, Ercolani, Giorgio
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis Group 01.12.2025
Témata:	Colorectal cancer Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Cytoreduction Surgical Procedures - methods cytoreductive surgery HIPEC Humans Hyperthermic Intraperitoneal Chemotherapy - methods Microsatellite Instability Mutation peritoneal metastasis Peritoneal Neoplasms - genetics Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics ras Proteins - genetics RAS/BRAF mutations microsatellite instability RAS/BRAF mutations HIPEC peritoneal metastasis Colorectal cancer cytoreductive surgery
ISSN:	0265-6736, 1464-5157, 1464-5157
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC. A literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded. Most studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist. RAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition.
AbstractList	Background Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC.Design A literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded.Results Most studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist.Conclusion RAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC. A literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded. Most studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist. RAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC.BACKGROUNDCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal metastases (PM) from colorectal cancer (CRC). Molecular alterations, particularly RAS/BRAF mutations and Microsatellite Instability (MSI), play crucial roles in prognostic stratification and treatment planning, influencing both disease-free survival (DFS) and overall survival (OS). This scoping review evaluates the prognostic role of MSI and RAS/BRAF mutations in patients with PM-CRC treated with CRS-HIPEC.A literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded.DESIGNA literature search was conducted across several databases to identify papers published between 2000 and September 2024. We selected 18 publications that considered DFS and OS as primary or secondary outcomes in patients with RAS/BRAF mutations and MSI following CRS-HIPEC treatment. Studies involving appendiceal cancer, peritoneal disease from non-CRC, pediatric patients, or subjects not treated with CRS-HIPEC were excluded.Most studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist.RESULTSMost studies suggest that RAS and BRAF mutations have a negative influence on survival outcomes. While inconsistencies exist, RAS mutations are generally associated with worse DFS. Specific KRAS subtypes such as KRASMUT2 or KRAS G12V and the BRAF V600 variant correlate with poorer prognosis. MSI status appears to attenuate the adverse effects of RAS/BRAF mutations on survival, although conflicting data persist.RAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition.CONCLUSIONRAS and BRAF mutations correlate with poorer outcomes in PM-CRC, underscoring the need for mutation-informed strategies to refine HIPEC and systemic therapies. Recognizing subtypes may improve patient selection for CRS-HIPEC, optimizing both local disease control and long-term survival. Future research should incorporate these molecular profiles to enhance therapeutic decision-making and better address this challenging condition.
Author	Pozzi, Eleonora Ercolani, Giorgio Turrini, Riccardo D’Acapito, Fabrizio Rapposelli, Ilario Giovanni Di Pietrantonio, Daniela Zucchini, Valentina Framarini, Massimo
Author_xml	– sequence: 1 givenname: Valentina surname: Zucchini fullname: Zucchini, Valentina – sequence: 2 givenname: Fabrizio surname: D’Acapito fullname: D’Acapito, Fabrizio – sequence: 3 givenname: Ilario Giovanni surname: Rapposelli fullname: Rapposelli, Ilario Giovanni – sequence: 4 givenname: Massimo surname: Framarini fullname: Framarini, Massimo – sequence: 5 givenname: Daniela surname: Di Pietrantonio fullname: Di Pietrantonio, Daniela – sequence: 6 givenname: Riccardo surname: Turrini fullname: Turrini, Riccardo – sequence: 7 givenname: Eleonora surname: Pozzi fullname: Pozzi, Eleonora – sequence: 8 givenname: Giorgio surname: Ercolani fullname: Ercolani, Giorgio
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40101749$$D View this record in MEDLINE/PubMed
BookMark	eNqFktFuFCEUhompsdvqI2i4NNFZYYBh0Kt109pNmmiqXhOGOVNpZoYRGJu-Sp-2jLvthTfeQML_nf_A4T9BR6MfAaHXlKwpqckHUlaikqxal6QU65JLJUr5DK0or3ghqJBHaLUwxQIdo5MYbwghPEMv0DEnlFDJ1Qrd74bJ2IR9h68239_jz1ebczzMySTnx4jN2OLB2eCjSdD3LgGOWZsjdiOeILiUb2V6PEAyWYgQcRf8gK3vfQCbsmTNaCHgFCBbtPjWpV_Y3qUst7NduuB3-GL37Wz7EUfrJzde4wB_HNy-RM8700d4ddhP0c_zsx_bi-Ly65fddnNZWMaULGrZSuClbFR-qWpr0yha0abmDVWMAmlZUzHS5VFwokTLFGUWpLUdVF0poGGnaLf3bb250VNwgwl32hun_x74cK1NSM72oDtVl1QqEE0neGmMkVA1hhNr2prXtsxeb_deU_C_Z4hJDy7aPDkzgp-jZlTWdV4qldE3B3RuBmifGj_-TQbEHljGHwN0TwglesmAfsyAXjKgDxnIdZ_-qbNu_58pGNf_p_oB7km2uQ
CitedBy_id	crossref_primary_10_1021_acsnano_5c01378 crossref_primary_10_1021_acsmedchemlett_5c00474 crossref_primary_10_1021_acsmedchemlett_5c00262
Cites_doi	10.1016/j.surge.2020.11.002 10.1186/s12957-022-02666-3 10.1097/DCR.0000000000000412 10.1200/JCO.2023.41.16_suppl.TPS3627 10.1007/s12094-023-03204-7 10.1245/s10434-023-13463-x 10.1093/jnci/djab001 10.1038/s41416-021-01620-6 10.1097/SLA.0000000000002899 10.1055/s-0043-1767705 10.1097/DCR.0000000000001914 10.1002/bjs5.50247 10.1245/s10434-024-15942-1 10.1016/j.ejso.2020.11.135 10.1016/S1470-2045(16)30500-9 10.1016/j.ejso.2013.10.001 10.1245/s10434-019-07378-9 10.1093/gastro/goad061 10.3390/cancers15010165 10.1055/s-0043-1761447 10.1245/s10434-021-11045-3 10.1200/JCO.20.02088 10.1038/s41467-019-11530-0 10.21294/1814-4861-2020-19-5-61-67 10.1002/cncr.26086 10.1093/annonc/mdw235 10.1016/j.jss.2019.02.050 10.1016/S1470-2045(22)00197-8 10.7326/M18-0850 10.1007/978-1-59259-160-2_22 10.1016/j.amjsurg.2016.03.008 10.1016/j.ejso.2022.06.014 10.1007/s00384-018-3091-x 10.18632/oncotarget.14012 10.3390/cancers13030467 10.1007/s11605-021-05073-3 10.1016/S1470-2045(10)70130-3 10.1016/S1470-2045(20)30599-4 10.1245/s10434-022-12704-9 10.1016/j.ejso.2024.108474 10.1016/j.esmoop.2024.102976
ContentType	Journal Article
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1080/02656736.2025.2479527
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1464-5157
ExternalDocumentID	oai_doaj_org_article_f982179e5bf542aaa7e6ba40cad848c2 40101749 10_1080_02656736_2025_2479527
Genre	Journal Article Scoping Review
GroupedDBID	--- 00X 0YH 29J 36B 4.4 5GY 5RE AALUX AAPXX AATTQ AAYXX ABDBF ABLKL ACGEJ ACGFS ACUHS ADBBV ADCVX ADRBQ ADXPE AENEX AFKVX AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS AQTUD BABNJ BCNDV BLEHA BOHLJ CCCUG CITATION CS3 DKSSO DU5 EAP EAS EBB EBC EBD EBO EBS EBX EHN EMB EMK EMOBN EPL EPT ESX F5P GROUPED_DOAJ H13 HZ~ I-F KRBQP KSSTO KTTOD KWAYT L7B O9- P2P QZIEQ Q~Q SV3 TDBHL TFDNU TFL TFW TH9 TUS V1S ~1N 53G 5VS AALIY ABUPF AGYJP AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE ECM EIF EJD M44 M4Z NPM QQXMO UDS ZGI 7X8
ID	FETCH-LOGICAL-c3397-87d7e427b96739d8ab9161b84b1931e0d3b630f2654095d3913ce7ccfe6f25eb3
IEDL.DBID	DOA
ISSN	0265-6736 1464-5157
IngestDate	Fri Oct 03 12:52:38 EDT 2025 Thu Jul 10 17:38:06 EDT 2025 Fri May 30 11:00:24 EDT 2025 Tue Nov 18 20:49:41 EST 2025 Sat Nov 29 08:11:13 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	microsatellite instability RAS/BRAF mutations HIPEC peritoneal metastasis Colorectal cancer cytoreductive surgery
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3397-87d7e427b96739d8ab9161b84b1931e0d3b630f2654095d3913ce7ccfe6f25eb3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
OpenAccessLink	https://doaj.org/article/f982179e5bf542aaa7e6ba40cad848c2
PMID	40101749
PQID	3178831769
PQPubID	23479
ParticipantIDs	doaj_primary_oai_doaj_org_article_f982179e5bf542aaa7e6ba40cad848c2 proquest_miscellaneous_3178831769 pubmed_primary_40101749 crossref_primary_10_1080_02656736_2025_2479527 crossref_citationtrail_10_1080_02656736_2025_2479527
PublicationCentury	2000
PublicationDate	2025-12-00
PublicationDateYYYYMMDD	2025-12-01
PublicationDate_xml	– month: 12 year: 2025 text: 2025-12-00
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	International journal of hyperthermia
PublicationTitleAlternate	Int J Hyperthermia
PublicationYear	2025
Publisher	Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis Group
References	e_1_3_3_30_1 Battaglin F (e_1_3_3_43_1) 2018; 16 e_1_3_3_18_1 e_1_3_3_17_1 e_1_3_3_39_1 e_1_3_3_19_1 e_1_3_3_14_1 e_1_3_3_13_1 e_1_3_3_38_1 e_1_3_3_16_1 e_1_3_3_35_1 e_1_3_3_15_1 e_1_3_3_36_1 e_1_3_3_10_1 e_1_3_3_33_1 e_1_3_3_34_1 e_1_3_3_12_1 e_1_3_3_31_1 e_1_3_3_11_1 e_1_3_3_32_1 e_1_3_3_40_1 e_1_3_3_41_1 e_1_3_3_7_1 e_1_3_3_6_1 e_1_3_3_9_1 e_1_3_3_8_1 e_1_3_3_29_1 e_1_3_3_28_1 e_1_3_3_25_1 e_1_3_3_24_1 e_1_3_3_27_1 e_1_3_3_26_1 e_1_3_3_3_1 e_1_3_3_21_1 e_1_3_3_44_1 e_1_3_3_2_1 e_1_3_3_20_1 Yazdi MH (e_1_3_3_37_1) 2015; 7 e_1_3_3_45_1 e_1_3_3_5_1 e_1_3_3_23_1 e_1_3_3_42_1 e_1_3_3_4_1 e_1_3_3_22_1
References_xml	– ident: e_1_3_3_2_1 – ident: e_1_3_3_31_1 doi: 10.1016/j.surge.2020.11.002 – ident: e_1_3_3_14_1 doi: 10.1186/s12957-022-02666-3 – ident: e_1_3_3_4_1 doi: 10.1097/DCR.0000000000000412 – ident: e_1_3_3_42_1 doi: 10.1200/JCO.2023.41.16_suppl.TPS3627 – ident: e_1_3_3_10_1 doi: 10.1007/s12094-023-03204-7 – ident: e_1_3_3_20_1 doi: 10.1245/s10434-023-13463-x – ident: e_1_3_3_24_1 doi: 10.1093/jnci/djab001 – ident: e_1_3_3_28_1 doi: 10.1038/s41416-021-01620-6 – ident: e_1_3_3_17_1 doi: 10.1097/SLA.0000000000002899 – ident: e_1_3_3_34_1 doi: 10.1055/s-0043-1767705 – ident: e_1_3_3_44_1 doi: 10.1097/DCR.0000000000001914 – ident: e_1_3_3_12_1 doi: 10.1002/bjs5.50247 – ident: e_1_3_3_23_1 doi: 10.1245/s10434-024-15942-1 – ident: e_1_3_3_8_1 doi: 10.1016/j.ejso.2020.11.135 – volume: 16 start-page: 735 issue: 11 year: 2018 ident: e_1_3_3_43_1 article-title: Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives publication-title: Clin Adv Hematol Oncol – ident: e_1_3_3_9_1 doi: 10.1016/S1470-2045(16)30500-9 – ident: e_1_3_3_7_1 doi: 10.1016/j.ejso.2013.10.001 – ident: e_1_3_3_18_1 doi: 10.1245/s10434-019-07378-9 – ident: e_1_3_3_27_1 doi: 10.1093/gastro/goad061 – ident: e_1_3_3_5_1 doi: 10.3390/cancers15010165 – ident: e_1_3_3_3_1 doi: 10.1055/s-0043-1761447 – ident: e_1_3_3_22_1 doi: 10.1245/s10434-021-11045-3 – ident: e_1_3_3_41_1 doi: 10.1200/JCO.20.02088 – ident: e_1_3_3_39_1 doi: 10.1038/s41467-019-11530-0 – ident: e_1_3_3_30_1 doi: 10.21294/1814-4861-2020-19-5-61-67 – ident: e_1_3_3_40_1 doi: 10.1002/cncr.26086 – ident: e_1_3_3_11_1 doi: 10.1093/annonc/mdw235 – ident: e_1_3_3_21_1 doi: 10.1016/j.jss.2019.02.050 – ident: e_1_3_3_45_1 doi: 10.1016/S1470-2045(22)00197-8 – ident: e_1_3_3_16_1 doi: 10.7326/M18-0850 – ident: e_1_3_3_19_1 doi: 10.1007/978-1-59259-160-2_22 – ident: e_1_3_3_32_1 doi: 10.1016/j.amjsurg.2016.03.008 – ident: e_1_3_3_26_1 doi: 10.1016/j.ejso.2022.06.014 – ident: e_1_3_3_6_1 doi: 10.1007/s00384-018-3091-x – ident: e_1_3_3_36_1 doi: 10.18632/oncotarget.14012 – ident: e_1_3_3_15_1 doi: 10.3390/cancers13030467 – ident: e_1_3_3_33_1 doi: 10.1007/s11605-021-05073-3 – ident: e_1_3_3_38_1 doi: 10.1016/S1470-2045(10)70130-3 – ident: e_1_3_3_13_1 doi: 10.1016/S1470-2045(20)30599-4 – ident: e_1_3_3_29_1 doi: 10.1245/s10434-022-12704-9 – ident: e_1_3_3_35_1 doi: 10.1016/j.ejso.2024.108474 – volume: 7 start-page: 134 issue: 4 year: 2015 ident: e_1_3_3_37_1 article-title: A comprehensive review of clinical trials on EGFR inhibitors such as cetuximab and panitumumab as monotherapy and in combination for treatment of metastatic colorectal cancer publication-title: Avicenna J Med Biotechnol – ident: e_1_3_3_25_1 doi: 10.1016/j.esmoop.2024.102976
SSID	ssj0004527
Score	2.441569
SecondaryResourceType	review_article
Snippet	Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with peritoneal... Background Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefits in select patients with...
SourceID	doaj proquest pubmed crossref
SourceType	Open Website Aggregation Database Index Database Enrichment Source
StartPage	2479527
SubjectTerms	Colorectal cancer Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - therapy Cytoreduction Surgical Procedures - methods cytoreductive surgery HIPEC Humans Hyperthermic Intraperitoneal Chemotherapy - methods Microsatellite Instability Mutation peritoneal metastasis Peritoneal Neoplasms - genetics Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics ras Proteins - genetics RAS/BRAF mutations
Title	Impact of RAS, BRAF mutations and microsatellite status in peritoneal metastases from colorectal cancer treated with cytoreduction + HIPEC: scoping review
URI	https://www.ncbi.nlm.nih.gov/pubmed/40101749 https://www.proquest.com/docview/3178831769 https://doaj.org/article/f982179e5bf542aaa7e6ba40cad848c2
Volume	42
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1464-5157 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004527 issn: 0265-6736 databaseCode: DOA dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1464-5157 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004527 issn: 0265-6736 databaseCode: TFW dateStart: 19850101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1464-5157 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004527 issn: 0265-6736 databaseCode: 0YH dateStart: 20180503 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1464-5157 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004527 issn: 0265-6736 databaseCode: 0YH dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s0WqAaJG6QksRPb3LZVV9sDVVVAWk6RX5EqdVO02UXqjSt_gh_HL2HGTpZeUC8ckoOdh-2Z2N_EM98w9sbXldbSucxblWeCG5PhlSELNTm0tT7PrYrJJuTJiVos9Om1VF_kE5bogdPAvW-1QtSsQ2XbSpTGGBlqa0TujFdCuTj74lNHY-ovT7hMf1eq6Nw-xu4QqzaWURHahmW1XwqpK0opc21ViuT9_0acceWZPWD3B8gI09TUh-xW6B6xux-HTfHH7NdxjHSEyxbOpp_ewcHZdAbLTdpj78F0HpbkdtebyL65DkBRRJsezjsgnmOi48bnL8PaYEUfeqCYEyA6a5oOscqRaqwgOqUHD_TvFtwVWuvE-0pv-f3j51s85senR4cfgCJdcEWEFBbzhH2ZHX0-nGdD2oXMcUQnOD96GUQprcZh0l4ZixCysEpYBHtFyD23Nc9bHEa0DSvPdcFdQHG3oW7LCo3zp2ynw5Y_Z1BLixY2RytTI-xS3JYKEZNF8bTB8JpPmBiHvXEDJzmlxrhoipG6dJBWQ9JqBmlN2P72tm-JlOOmGw5IptuLiVM7FqCmNYOmNTdp2oS9HjWiwW-QNlZMFy43fYMYDHtZyFpP2LOkKttXCSLxk0Lv_o8mvGD3qFvJneYl21mvNuEVu-O-r8_71R67nX-d41ku1F78HP4A79wKHA
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+RAS%2C+BRAF+mutations+and+microsatellite+status+in+peritoneal+metastases+from+colorectal+cancer+treated+with+cytoreduction%E2%80%89%2B%E2%80%89HIPEC%3A+scoping+review&rft.jtitle=International+journal+of+hyperthermia&rft.au=Zucchini%2C+Valentina&rft.au=D%27Acapito%2C+Fabrizio&rft.au=Rapposelli%2C+Ilario+Giovanni&rft.au=Framarini%2C+Massimo&rft.date=2025-12-01&rft.eissn=1464-5157&rft.volume=42&rft.issue=1&rft.spage=2479527&rft_id=info:doi/10.1080%2F02656736.2025.2479527&rft_id=info%3Apmid%2F40101749&rft.externalDocID=40101749
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-6736&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-6736&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-6736&client=summon